LONDON — A bidding war has broken into the open for obesity-focused Metsera, with Novo Nordisk on Thursday saying it had made an offer for the biotech, a month after Pfizer announced its plan to purchase the firm.
The Novo offer, what it called “an unsolicited proposal,” reflects the pressure pharma companies are under to gain an edge in the white-hot obesity market. It also seems to have gained traction with Metsera.
After Novo announced its move, which Pfizer called “reckless and unprecedented,” Metsera issued a statement saying it considered the Danish firm’s offer “superior” and delivered a notice to Pfizer saying as much. Under the terms of its agreement with Pfizer, Metsera said, that notice now means Pfizer has four business days to renegotiate the terms of its offer.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
Source link
